Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: a critical review of published data

In recent years, the immune-checkpoint inhibitors (ICIs) used in monotherapy or combination with other compounds, changed the management of metastatic non-small cell lung cancer (NSCLC), without oncogene alterations (Tables 1-2). 1-15

Source: Cancer Treatment Reviews - July 20, 2020 Category: Cancer & Oncology Authors: Antonio Passaro, Ilaria Attili, Stefania Morganti, Ester Del Signore, Letizia Gianoncelli, Gianluca Spitaleri, Valeria Stati, Chiara Catania, Giuseppe Curigliano, Filippo de Marinis Tags: Anti-tumour Treatment Source Type: research